Japanese company profile · 4583

Chiome Bioscience Inc.

In its FY2025 public filing, Chiome Bioscience Inc. reports Drug Discovery, Drug Discovery Support Business. The page shows business-level revenue and profit where the source disclosures support comparison.

Original Japanese company name: 株式会社カイオム・バイオサイエンス

English company name recorded in Japan's EDINET filer data. English company name source

What does this company do?

The business with the highest reported segment profit in FY2025 was Drug Discovery Support Business.

FY2025 · fiscal year ended December 2025 View original filing ↗ The source document may be in Japanese.

Business structure

How does it make money?

Business	Sales	Revenue share	Operating profit
Drug Discovery Support Business	¥593.29M ↗	—	¥355.58M ↗
Drug Discovery	—	—	−¥776.54M ↗

All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended December 2025. Revenue and profit are shown only where the filing and data support a comparison.

Original Japanese label

Drug Discovery: 創薬事業
Drug Discovery Support Business: 創薬支援事業
Sales: 売上高
Operating profit: 営業利益

Original Japanese label

Drug Discovery: 創薬事業
Drug Discovery Support Business: 創薬支援事業
Sales: 売上高
Operating profit: 営業利益

What is growing?

Business revenue growth

Drug Discovery Support Business

Reported revenue in 2021 ¥609.92M Reported revenue in 2025 ¥593.29M

growth amount: −¥16.63M
growth annualized: -0.7%
growth total: -2.7%

FY2021–FY2025

View original filing

Drug Discovery Support Business

Reported profit margin in 2022 +55.3%

Reported profit margin in 2025 +59.9%

growth margin points: +4.6

FY2022–FY2025

View original filing

This describes a reported period; it is not a forecast.

What has changed?

Not disclosed or not safely comparable in the available filings.

Source

Public filing

FY2025 · fiscal year ended December 2025

The source document may be in Japanese.

Filing ID: S100XUJT

View original filing ↗

Ask about this company

The source document may be in Japanese.